A Connecticut firm is in the race to develop an Ebola vaccine

Aug 7, 2014

As the deadly Ebola virus continues to devastate several countries in West Africa, a Connecticut biotech lab is one of a number of U.S. firms racing to develop a vaccine.

CEO of West Haven-based NanoViricides is Dr. Eugene Seymour. He’s optimistic that an Ebola vaccine can soon be developed using his company’s biotech machines.

“I feel that using our platform we could have a drug that would be unbelievably effective against Ebola in the space of three weeks,” he said on Wednesday.

Currently there are no licensed drugs or vaccines for Ebola, although some vaccines and other drugs have entered clinical trials. The vaccine being developed by the West Haven lab would have to be approved by government authorities before it could be administered to Ebola victims.